目的：探讨小分子多靶点抗血管生成药物联合使用对RET原癌基因突变的晚期肺腺癌患者的治疗效果。方法：通过解析本院确诊的1例RET突变的晚期肺腺癌患者的详细治疗过程，计算患者不同治疗方案的无进展生存时间（PFS），评估不同药物的治疗效果。结果：本例患者最初接受了培美曲塞联合顺铂的方案化疗4个周期后疾病进展，PFS为94 d；调整治疗方案为多西他赛单药化疗4个周期并联合低剂量阿帕替尼（250 mg·d^-1）抗血管生成治疗后，患者疾病部分缓解，PFS为88 d；疾病再次进展后改用卡博替尼单药（60 mg·d^-1）靶向治疗2周后无效，PFS为0 d，但联合低剂量阿帕替尼（250 mg·d^-1）抗血管生成后，患者胸水较前显著吸收，PS评分较前改善，疾病部分缓解，PFS为46 d。结论：本例RET突变的晚期肺腺癌患者对化疗有效，对卡博替尼单药靶向治疗无效，但对低剂量的阿帕替尼（250 mg·d^-1）联合卡博替尼反应良好。

[1] 陈君,黄佳丽,程志祥.奥希替尼对晚期非小细胞肺癌的治疗进展[J].东南大学学报(医学版),2020,39(1):85-89.
[2] 刘贞,王彩莲.非小细胞肺癌靶向治疗回顾与进展[J].现代医学,2018,46(2):229-234.
[3] DRILON A,WANG L,HASANOVIC A,et al.Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas[J].Cancer Discov,2013,3(6):630-635.
[4] FERRARA R,AUGER N,AUCLIN E.Clinical and translational implications of RET rearrangements in non-small cell lung cancer[J].J Thorac Oncol,2018,13(1):27-45.
[5] YU H A,SCHOENFELD A J,MAKHNIN A,et al.Effect of Osimertinib and Bevacizumabon Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers:A Phase 1/2 Single-Group Open-Label Trial[J].JAMA Oncol,2020,6(7):1-8.
[6] WANG R,HU H,PAN Y,et al.RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer[J].J Clin Oncol,2012,30(35):4352-4359.
[7] TSUTA K,KOHNO T,YOSHIDA A,et al.RET-rearranged non-small-cell lung carcinoma:a clinicopathological and molecular analysis[J].Br J Cancer,2014,110(6):1571-1578.
[8] JU Y S,LEE W C,SHIN J Y,et al.A transforming KIF5B and RET gene fusion in lungadenocarcinoma revealed from whole-genome and transcriptome sequencing[J].Genome Res,2012,22(3):436-445.
[9] DRILON A,REKHTMAN N,ARCILA M,et al.Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer:an open-label,single-centre,phase 2,single-arm trial[J].Lancet Oncol,2016,17(12):1653-1660.
[10] FALCON B L,CHINTHARLAPALLI S,UHLIK M T.Antagonist antibodies to vascular endothelial growth factor receptor 2(VEGFR-2) as anti-angiogenic agents[J].Pharmacol Ther,2016,164:204-225.
[11] TIAN S,QUAN H,XIE C,et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Sci,2011,102(7):1374-1380.
[12] TONG X Z,WANG F,LIANG S,et al.Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells[J].Biochem Pharmacol,2012,83(5):586-597.
[13] XU J,LIU X,YANG S,et al.Clinical response to apatinib monotherapy in advanced non-small cell lung cancer[J].Asia Pac J Clin Oncol,2018,14(3):264-269.
[14] LIU Z, OU W, LI N,et al.Apatinib monotherapy for advanced non-small celllung cancer after the failure of chemotherapy or other targeted therapy[J].Thorac Cancer,2018,9(10):1285-1290.
[15] SAITO H, FUKUHARA T, FURUYA N, et al.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026):interim analysis of an open-label,randomised,multicentre,phase 3 trial[J].Lancet Oncol,2019,20(5):625-635.
[16] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009,45(2):228-247.
[17] LI F,ZHU T,CAO B,et al.Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance[J].Eur J Cancer,2017,84:184-192.
[18] MENDEL D B,LAIRD A D,XIN X,et al.In vivo antitumor activity of SU11248,a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors:determination of a pharmacokinetic/pharmacodynamic relationship[J].Clin Cancer Res,2003,9(1):327-337.
[19] LIN C,WANG S,XIE W,et al.Apatinib inhibits cellular invasion and migration byfusion kinase KIF5B-RET via suppressing RET/Src signaling pathway[J].Oncotarget,2016,7(37):59236-59244.